Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma (BiovaxID)
This study is ongoing, but not recruiting participants.
Study NCT00091676   Information provided by Biovest International
First Received: September 15, 2004   Last Updated: February 1, 2012   History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study
About Study Results Reporting on ClinicalTrials.gov
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2012
  Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Publications:
Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011 Jul 10;29(20):2787-94. Epub 2011 May 31.




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services